Functional characterization of eight human cytochrome P450 1A2 gene variants by recombinant protein expression

Pharmacogenomics Journal

Volumn 10, Issue 6, 2010, Pages 478-488

  Palma, B B ^a,b   Sousa, M S ^a   Vosmeer, C R ^b   Lastdrager, J ^b   Rueff, J ^a   Vermeulen, N P E ^b   Kranendonk, M ^a  

^a UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

CYP1A2; cytochrome P450; pharmacogenomics; pharmacokinetics; polymorphisms

Indexed keywords

4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; APOPROTEIN; CLOZAPINE; CYTOCHROME P450 1A2; HEME; LIPOPROTEIN; PHENACETIN; RECOMBINANT PROTEIN;

ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DRUG METABOLISM; DRUG STRUCTURE; ENZYME ACTIVITY; ESCHERICHIA COLI; GENETIC ENGINEERING; GENETIC VARIABILITY; HUMAN; MICHAELIS MENTEN KINETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN POLYMORPHISM; SITE DIRECTED MUTAGENESIS; XENOBIOTIC METABOLISM;

CLONING, MOLECULAR; CYTOCHROME P-450 CYP1A2; ESCHERICHIA COLI; HEME; HUMANS; MUTAGENESIS, SITE-DIRECTED; NADPH-FERRIHEMOPROTEIN REDUCTASE; NITROSAMINES; POLYMORPHISM, GENETIC; RECOMBINANT PROTEINS;

ESCHERICHIA COLI;

EID: 78649330101     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2010.2     Document Type: Article

References (55)

1. Ingelman-Sundberg M. Genetic susceptibility to adverse effects of drugs and environmental toxicants. The role of the CYP family of enzymes. Mutat Res 2001; 482: 11-19.
2. Cascorbi I. Genetic basis of toxic reactions to drugs and chemicals. Toxicol Lett 2006; 162: 16-28.
3. Ingelman-Sundberg M. Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J Intern Med 2001; 250: 186-200.
4. Guengerich FP. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem Res Toxicol 2001; 14: 611-650.
5. Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annu Rev Med 2006; 57: 119-137.
6. Guengerich FP. Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J 2006; 8: E101-E111.
7. Zhou H, Josephy PD, Kim D, Guengerich FP. Functional characterization of four allelic variants of human cytochrome P450 1A2. Arch Biochem Biophys 2004; 422: 23-30.
8. Ingelman-Sundberg M. Polymorphism of cytochrome P450 and xenobiotic toxicity. Toxicology 2002; 181-182: 447-452.
9. Jiang Z, Dalton TP, Jin L, Wang B, Tsuneoka Y, Shertzer HG et al. Toward the evaluation of function in genetic variability: characterizing human SNP frequencies and establishing BAC-transgenic mice carrying the human CYP1A1-CYP1A2 locus. Hum Mutat 2005; 25: 196-206.
10. Jiang Z, Dragin N, Jorge-Nebert LF, Martin MV, Guengerich FP, Aklillu E et al. Search for an association between the human CYP1A2 genotype and CYP1A2 metabolic phenotype. Pharmacogenet Genom 2006; 16: 359-367.
11. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Inter-individual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270: 414-423.
12. Guengerich FP In: Ortiz de Montellano P (ed) Cytochrome P450 Structure, Mechanism and Biochemistry. Kluwer, Academic/Plenum Publishers: New York, 2005 pp 377-560.
13. Yun CH, Miller GP, Guengerich FP. Rate-determining steps in phenacetin oxidations by human cytochrome P450 1A2 and selected mutants. Biochemistry 2000; 39: 11319-11329.
14. Olesen OV, Linnet K. Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations. J Clin Pharmacol 2001; 41: 823-832.
15. Eiermann B, Engel G, Johansson I, Zanger UM, Bertilsson L. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol 1997; 44: 439-446.
16. Tracy TS, Marra C, Wrighton SA, Gonzalez FJ, Korzekwa KR. Involvement of multiple cytochrome P450 isoforms in naproxen O-demethyla-tion. Eur J Clin Pharmacol 1997; 52: 293-298.
17. Johnson JA, Herring VL, Wolfe MS, Relling MV. CYP1A2 and CYP2D6 4-hydroxylate propranolol and both reactions exhibit racial differences. J Pharmacol Exp Ther 2000; 294: 1099-1105.
18. Granfors MT, Backman JT, Laitila J, Neuvonen PJ. Tizanidine is mainly metabolized by cytochrome p450 1A2 in vitro. Br J Clin Pharmacol 2004; 57: 349-353.
19. Ikeya K, Jaiswal AK, Owens RA, Jones JE, Nebert DW, Kimura S. Human CYP1A2: sequence, gene structure, comparison with the mouse and rat orthologous gene, and differences in liver 1A2 mRNA expression. Mol Endocrinol (Baltimore, MD) 1989; 3: 1399-1408.
20. Saruwatari J, Nakagawa K, Shindo J, Tajiri T, Fujieda M, Yamazaki H et al. A population phenotyping study of three drug-metabolizing enzymes in Kyushu, Japan, with use of the caffeine test. Clin Pharmacol Ther 2002; 72: 200-208.
21. Guengerich FP, Parikh A, Turesky RJ, Josephy PD. Inter-individual differences in the metabolism of environmental toxicants: cytochrome P450 1A2 as a prototype. Mutat Res 1999; 428(1-2): 115-124.
22. Murayama N, Soyama A, Saito Y, Nakajima Y, Komamura K, Ueno K et al. Six novel nonsynonymous CYP1A2 gene polymorphisms: catalytic activities of the naturally occurring variant enzymes. J Pharmacol Exp Ther 2004; 308: 300-306.
23. Saito Y, Hanioka N, Maekawa K, Isobe T, Tsuneto Y, Nakamura R et al. Functional analysis of three CYP1A2 variants found in a Japanese population. Drug Metab Dispos 2005; 33: 1905-1910.
24. Sansen S, Yano JK, Reynald RL, Schoch GA, Griffin KJ, Stout CD et al. Adaptations for the oxidation of polycyclic aromatic hydrocarbons exhibited by the structure of human P450 1A2. J Biol Chem 2007; 282: 14348-14355.
25. Fisher CW, Caudle DL, Martin-Wixtrom C, Quattrochi LC, Tukey RH, Waterman MR et al. High-level expression of functional human cytochrome P450 1A2 in Escherichia coli. FASEB J 1992; 6: 759-764.
26. Duarte MP, Palma BB, Laires A, Oliveira JS, Rueff J, Kranendonk M. Escherichia coli BTC, a human cytochrome P450 competent tester strain with a high sensitivity towards alkylating agents: involvement of alkyltransferases in the repair of DNA damage induced by aromatic amines. Mutagenesis 2005; 20: 199-208.
27. Bauer S, Shiloach J. Maximal exponential growth rate and yield of E. coli obtainable in a bench-scale fermentor. Biotechnol Bioeng 1974; 16: 933-941.
28. Kranendonk M, Carreira F, Theisen P, Laires A, Fisher CW, Rueff J et al. Escherichia coli MTC, a human NADPH P450 reductase competent mutagenicity tester strain for the expression of human cytochrome P450 isoforms 1A1, 1A2, 2A6, 3A4, or 3A5: catalytic activities and mutagenicity studies. Mutat Res 1999; 441: 73-83.
29. Kranendonk M, Marohnic CC, Panda SP, Duarte MP, Oliveira JS, Masters BS et al. Impairment of human CYP1A2-mediated xenobiotic metabolism by Antley-Bixler syndrome variants of cytochrome P450 oxidoreductase. Arch Biochem Biophys 2008; 475: 93-99.
30. Chauret N, Gauthier A, Nicoll-Griffith DA. Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes. Drug Metab Dispos 1998; 26: 1-4.
31. Damsten MC, van Vugt-Lussenburg BM, Zeldenthuis T, de Vlieger JS, Commandeur JN, Vermeulen NP. Application of drug metabolising mutants of cytochrome P450 BM3 (CYP102A1) as biocatalysts for the generation of reactive metabolites. Chem Biol Interact 2008; 171: 96-107.
32. Kranendonk M, Mesquita P, Laires A, Vermeulen NP, Rueff J. Expression of human cytochrome P450 1A2 in Escherichia coli: a system for biotransformation and genotoxicity studies of chemical carcinogens. Mutagenesis 1998; 13: 263-269.
33. Urban P, Truan G, Pompon D. Differences in functional clustering of endogenous and exogenous substrates between members of the CYP1A Subfamily. Open Drug Metab J 2009; 3: 17-30.
34. Jolliffe IT. Principal Component Analysis. Springer: New York, 1986.
35. Cox TFC, Cox MAA. Multidimensional Scaling. Chapman & Hall: London, 2001.
36. Venkatakrishnan K, von Moltke LL, Court MH, Harmatz JS, Crespi CL, Greenblatt DJ. Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metab Dispos 2000; 28: 1493-1504.
37. Ghotbi R, Christensen M, Roh HK, Ingelman-Sundberg M, Aklillu E, Bertilsson L. Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol 2007; 63: 537-546.
38. Bohanec Grabar P, Rozman B, Toms?ic? M, S?uput D, Logar D, Dolz?an V. Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients. Eur J Clin Pharmacol 2008; 64: 871-876.
39. Spina E, de Leon J. Metabolic drug interactions with newer anti-psychotics: a comparative review. Basic Clin Pharmacol Toxicol 2007; 100: 4-22.
40. Suzuki H, Morris JS, Li Y, Doll MA, Hein DW, Liu J et al. Interaction of the cytochrome P4501A2, SULT1A1 and NAT gene polymorphisms with smoking and dietary mutagen intake in modification of the risk of pancreatic cancer. Carcinogenesis 2008; 29: 1184-1191.
41. Altayli E, Gunes S, Yilmaz AF, Goktas S, Bek Y. CYP1A2, CYP2D6, GSTM1, GSTP1, and GSTT1 gene polymorphisms in patients with bladder cancer in a Turkish population. Int Urol Nephrol 2009; 41: 259-266.
42. Miller-Jensen K, Janes KA, Brugge JS, Lauffenburger DA. Common effector processing mediates cell-specific responses to stimuli. Nature 2007; 448(7153): 604-608.
43. Kurtovic S, Shokeer A, Mannervik B. Diverging catalytic capacities and selectivity profiles with haloalkane substrates of chimeric alpha class glutathione transferases. Protein Eng Des Sel 2008; 21: 329-341.
44. Xu W, Ahmed S, Moriyama H, Chollet R. The importance of the strictly conserved, C-terminal glycine residue in phosphoenolpyruvate carbox-ylase for overall catalysis: mutagenesis and truncation of GLY-961 in the sorghum C4 leaf isoform. J Biol Chem 2006; 281: 17238-17245.
45. Otu HH, Naxerova K, Ho K, Can H, Nesbitt N, Libermann TA et al. Restoration of liver mass after injury requires proliferative and not embryonic transcriptional patterns. J Biol Chem 2007; 282: 11197-11204.
46. Sevrioukova IF, Li H, Zhang H, Peterson JA, Poulos TL. Structure of a cytochrome P450-redox partner electron-transfer complex. Proc Natl Acad Sci USA 1999; 96: 1863-1868.
47. Cojocaru V, Winn PJ, Wade RC. The ins and outs of cytochrome P450s. Biochim Biophys Acta 2007; 1770: 390-401.
48. Seifert A, Pleiss J. Identification of selectivity-determining residues in cytochrome P450 monooxygenases: a systematic analysis of the substrate recognition site 5. Proteins 2009; 74: 1028-1035.
49. Furuya H, Shimizu T, Hatano M, Fujii-Kuriyama Y. Mutations at the distal and proximal sites of cytochrome P-450d changed regio-specificity of acetanilide hydroxylations. Biochem Biophys Res Commun 1989; 160: 669-676.
50. Furuya H, Shimizu T, Hirano K, Hatano M, Fujii-Kuriyama Y, Raag R et al. Site-directed mutageneses of rat liver cytochrome P-450d: catalytic activities toward benzphetamine and 7-ethoxycoumarin. Biochemistry 1989; 28: 6848-6857.
51. Oprea TI, Hummer G, Garcia AE. Identification of a functional water channel in cytochrome P450 enzymes. Proc Natl Acad Sci USA 1997; 94: 2133-2138.
52. Zanger UM, Turpeinen M, Klein K, Schwab M. Functional pharmaco-genetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 2008; 392: 1093-1108.
53. Solus JF, Arietta BJ, Harris JR, Sexton DP, Steward JQ, McMunn C et al. Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics 2004; 5: 895-931.
54. Huang JD, Guo WC, Lai MD, Guo YL, Lambert GH. Detection of a novel cytochrome P-450 1A2 polymorphism (F21L) in Chinese. Drug Metab Dispos 1999; 27: 98-101.
55. Chevalier D, Cauffiez C, Allorge D, Lo-Guidice JM, Lhermitte M, Lafitte JJ et al. Five novel natural allelic variants-951A4C, 1042G4A (D348N), 1156A4T (I386F), 1217G4A (C406Y) and 1291C4T (C431Y)-of the human CYP1A2 gene in a French Caucasian population. Hum Mutat 2001; 17: 355-356.